A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine

Cindy Hörnera,b,1, Christoph Schürmanna,1, Arne Auste,b,d, Aileen Ebenig, Samada Muraleedharam, Kenneth H. Dinnon IIIc, Tatjana Scholzd, Maike Herrmanna,e, Barbara S. Schnierlef, Ralph S. Baricg,h, and Michael D. Mühlebacha,b,2

The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread worldwide, with millions of cases and more than 1 million deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles viruses (MeVs) with different expression levels of the SARS-CoV-2 spike protein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+ and CD4+ T cell responses with S protein-specific killing activity were detected. Upon challenge using a mouse-adapted SARS-CoV-2, virus loads in vaccinated animals were significantly lower, while vaccinated Syrian hamsters revealed protection in a harsh challenge setup using an early-passage human patient isolate. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines.

SARS-CoV-2 | COVID-19 | measles vaccine platform | effective immunity | Th1 immune bias

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to Coronavirusidae family and emerged toward the end of 2019 as causative agent of pneumonia in the Hubei province in China (1). The World Health Organization named the disease Coronavirus Disease-2019 (COVID-19), and officially declared the pandemic state on March 11, 2020. Human coronaviruses have been known for decades as one of the causative agents of the common cold, but two previous coronavirus outbreaks, caused by the severe acute respiratory syndrome virus (SARS-CoV-1) and the Middle East respiratory syndrome virus (MERS-CoV), have demonstrated the remarkable pathogenic potential of human beta coronaviruses. Around 10,000 people have been infected by SARS and MERS, which has resulted in a death toll of about 1,500 patients, but the outbreaks remained largely confined in terms of time or spread, respectively. In contrast, SARS-CoV-2 spreads effectively and at a rapid pace by direct transmission, with a reproductive number $R_0$ of at least 2 to 2.5 (2, 3). Due to high transmissibility and extensive community spread, this novel coronavirus has already caused over 36.2 million infections and over 1 million deaths (as of October 9, 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019), while worldwide shutdowns of social life and economy to confine the spread of this respiratory virus have considerable impacts.

After the emergence of SARS in 2002 and then MERS in 2012, vaccine development efforts have been initiated, including the use of recombinant measles virus (MeV) vaccine as a platform concept (4), to develop vector vaccine candidates against both agents, and showed promising results. Recombinant MeV vectors encoding the unmodified SARS-CoV Spike protein induced high titers of neutralizing antibodies as well as IFN-γ T cell responses (5, 6) and conferred protection to immunized animals upon pathogen challenge by lowering virus titers more than 100-fold (5). For MERS, we have demonstrated that high titers of neutralizing antibodies as well as effective and polyfunctional T cell responses were induced in vaccinated animals (7, 8) and conferred protection (7). Based on these data, an MeV-based MERS vaccine candidate has been selected by the Coalition for Epidemic Preparedness Initiative for further clinical development (http://www.cepi.net/research_dev/our-portfolio).

Here, we explored the potential of recombinant MeV as vectors for the expression of the SARS-CoV-2 spike protein (S) as successfully applied for the development of MERS (7, 8) and SARS (5, 6) vaccine candidates, as well as numerous other pathogens (4). The S glycoprotein was chosen as antigen for its role as primary target of neutralizing antibodies (6, 7) and the exemplary capability of MERS-CoV S protein to trigger strong cell-mediated immune responses when expressed by MeV in our front-runner

Significance

The COVID-19 pandemic has already caused over 1 million deaths. Therefore, effective vaccine concepts are urgently needed. In search of such a concept, we have analyzed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well-known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity, yielding antiviral efficacy in vivo with the desired immune bias. Consequently, no immunopathologies became evident during challenge experiments. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats.

Author contributions: M.D.M. designed research; C.H., C.S., A.A., A.E., S.M., and T.S. performed research; K.H.D., M.H., B.S.S., and R.S.B. contributed new reagents/analytic tools; C.H., C.S., A.A., A.E., S.M., M.H., and M.D.M. analyzed data; C.H., S.M., and M.D.M. wrote the paper; M.H. developed bioinformatics pipeline; and M.D.M. supervised research.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

1C.H. and C.S. contributed equally to this work.

2To whom correspondence may be addressed. Email: Michael.Muehlebach@pei.de.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2014468117/-/DCSupplemental.
MERS vaccine candidate (7, 8). The SARS-CoV-2 S protein-encoding gene was inserted into two different positions of the MeV genome to modulate antigen expression, and both recombinant MeVs were successfully rescued. The virus expressing lower S protein levels resulted in stable amplification over at least 10 passages, while impairment of replication was insignificant. Indeed, immunization of IFNAR−/−/CD46Ge mice induced strong and functional humoral and cellular immune responses directed against both MeV and SARS-CoV-2 S protein biased for Th1-type T cell and antibody responses. The induced immunity translated in antiviral efficacy in two different challenge models, that is, vaccinated hamsters and mice, thereby illustrating the potential of MeV platform-based COVID-19 vaccine candidates.

Results

Generation and Characterization of SARS-CoV-2-S by Recombinant MeVvac2. Since the SARS-CoV and MERS-CoV S proteins have been shown to potentially induce humoral and cellular immune responses, the SARS-CoV-2 S protein was chosen as an appropriate antigen to be expressed by the recombinant MeV vaccine platform. A codon-optimized full-length gene encoding SARS-CoV-2 S protein was cloned into two different additional transcription units (ATUs) in the vaccine strain MeVvac2 genome, either downstream of the P (post P) or H (post H) gene cassettes (Fig. 1L). Recombinant viruses were successfully generated and amplified up to P10 in Vero cells with titers of up to 4 × 10^7 50% tissue culture infectious doses (TCID50)/mL. The stability of the viral genomes was demonstrated via sequencing after RT-PCR of viruses in P2 or P10. In parallel to Sanger sequencing of the ATU region encompassing the SARS-CoV-2-S gene, the full genome was sequenced using next-generation sequencing (NGS) with a coverage of 4 to 29,683 reads of each position (SI Appendix, Fig. S1) in P2. Both methods revealed no mutations across the whole vaccine genomes but a single A to G substitution on position 9 of the noncoding trailer region of the MeVvac2-SARS2-S(H) clone used for in vivo studies (GenBank accession no. MW090971).

To verify SARS-CoV-2 S protein expression levels, Western blot analysis of Vero cells infected with the MeVvac2-SARS2-S vaccine was performed. The S protein expression was slightly attenuated when cells were infected with viruses encoding the antigen in the ATU post-P construct compared to the post-H construct (Fig. 1E). However, there was less overall viral protein expression in cells infected with post-P construct. Comparative growth kinetics with the vaccine viruses containing the SARS-CoV-2-S gene and the MeVvac2-ATU(P) control virus revealed that the MeVvac2 encoding full-length SARS-CoV-2 S gene in post-P position grew remarkably different than the control virus, with ~100-fold reduced maximal titers. In contrast, growth of MeVvac2-SARS2-S(H) was much closer to MeVvac2-ATU(P), with only a slight trend for lower titers (Fig. 1 C and D).

The impaired growth of MeVvac2-SARS2-S(P) was accompanied by a hyperfusogenic phenotype (Fig. 1E and SI Appendix, Fig. S2A), which was also observed for the post-H vaccine candidate, but to a lesser extent. Therefore, fusion activity was quantified and compared to the parental MeVvac2-ATU(P) as well as the MVNgSeGFP(N), which is known for its hyperfusogenic phenotype due to a V94M substitution in the F2 subunit of the MeV fusion protein (9). MVVac2-ATU(P) induced fusion of 16.8 ± 0.8 (mean ± SD) Vero cells 30 h after infection. MeVvac2-SARS2-S(P) revealed approximately fourfold enhanced fusion activity (syncytia including 70 ± 8 cells), while MeVvac2-SARS2-S(H) just fused 41 ± 6 cells, thereby representing an intermediate phenotype. However, fusion activity of the latter was surpassed by MVNgSeGFP(N) that fused 56 ± 4 cells in 30 h under the same conditions (SI Appendix, Fig. S2B).

To investigate whether this increased fusion activity is due to SARS-CoV-2 S protein-mediated cell-to-cell fusion, we expressed the SARS-CoV-2 S protein by transfection of the eukaryotic expression plasmid pcDNA3.1-SARS2-S into SARS-CoV-2 receptor hACE2-negative 293T as well as into receptor-positive Vero cells. Indeed, expression of SARS-CoV-2 S protein induced syncytia of Vero, but not of 293T cells (SI Appendix, Fig. S3).

These data demonstrate that the hyperfusogenic phenotype of the SARS-CoV-2 S-encoding MeV is linked to expression of a fusion-active form of the SARS-CoV-2 S protein, indicating that cells infected by the vaccine candidates express a functional S protein. Thus, cloning and rescue of MeVs expressing correctly fused SARS-CoV-2-S(H) was chosen for further characterization in vivo.

MeVvac2-SARS2-S(H) Induces Neutralizing Antibodies against MeV and SARS-CoV-2. To test the efficacy of MeVvac2-SARS2-S(H) in vivo, genetically modified IFNAR−/−/CD46Ge mice were used, since they are the prime small animal model for analysis of MeV-derived vaccines (10). Groups of six to seven animals were immunized via the intraperitoneal route on days 0 and 28 with 1 × 10^7 TCID50 of MeVvac2-SARS2-S(H) or empty MeVvac2-ATU(P) as a control. As positive control, recombinant SARS-CoV-2 S protein adjuvanted with aluminum hydroxide gel (Alum) was injected subcutaneously, and medium-inoculated mice served as mock controls. Twenty-one days after the second immunization, sera of immunized mice were analyzed in comparison to prebled and postprime immunization sera, by ELISA on antigen-coated plates, for total IgG antibodies binding to MeV bulk antigens (Fig. 2 G–I) or SARS-CoV-2 S protein (Fig. 2 A–C). Sera of mice vaccinated with MeVvac2-SARS2-S(H) contained IgG antibodies that bound to SARS-CoV-2 S protein (Fig. 2 B and C), whereas no antibodies were found in mice before vaccination (Fig. 2A), or in MeV or mock-immunized control mice. Moreover, final sera of mice vaccinated with any recombinant MeV had IgG in the serum binding to MeV bulk antigens, indicating at least one successful vaccination with MeVs and general vector immunogenicity (Fig. 2 G–I). The control S protein vaccine did induce higher levels of S protein-binding IgG than MeVvac2-SARS2-S(H) (Fig. 2C).

We next determined the neutralizing antibody responses against SARS-CoV-2 (Fig. 2 D–F) or MeV (Fig. 2 J–L). Most immunized groups reacted with the control virus, had developed MeV neutralizing antibody titers (virus neutralization titer [VNT]) after the first immunization (Fig. 2K). However, two mice of the MeVvac2-SARS2-S(H) cohort initially reacted only weakly, and another mouse reacted not at all, reflecting individual differences in response to immunization. All animals had developed neutralizing antibodies after the second immunization, and a threefold increase was observed upon the second immunization (220 to 762 VNT; Fig. 2 K and L). Neutralizing antibodies against SARS-CoV-2 were detected in mice vaccinated with MeVvac2-SARS2-S(H) after the second immunization, and reached a titer of 15 to 80 in three out of seven mice (Fig. 2F). These titers were in the range of human convalescent sera tested in parallel (VNT 10 to 60; SI Appendix, Fig. S4). No VNTs against MeV or SARS-CoV-2 were detected in control mice inoculated with medium alone. Interestingly, the Alum-adjuvanted recombinant S protein did not induce any neutralizing antibodies despite higher binding IgG levels in ELISA, indicating that these antibodies bind to other epitopes of S or with lower affinity than those induced by the MeV-based vaccine candidate. In summary, the SARS-CoV-2 S protein-expressing MeV elicited robust neutralizing antibody responses against MeV and SARS-CoV-2.

Splenocytes of Animals Vaccinated with MeVvac2-SARS2-S(H) React to SARS-CoV-2 S Protein-Specific Stimulation. To assess the ability of MeVvac2-SARS2-S(H) to induce SARS-CoV-2–specific cellular
immune responses, splenocytes of vaccinated animals were analyzed for antigen-specific IFN-γ secretion by Enzyme-Linked Immunosorbent Spot (ELISpot) assay. Toward this, antigen-specific T cells were restimulated by cocultivation with the syngeneic murine dendritic cell (DC) cell lines JAWSII or DC2.4 stably expressing the SARS-CoV-2 S protein. For JAWSII cells, bulk cultures of transduced cells were obtained by flow cytometric sorting. For DC2.4 cells, single-cell clones were generated by limiting dilution of sorted bulk cultures. Antigen expression by transduced DCs was verified by Western blot analysis and flow cytometry (SI Appendix, Fig. S5).

ELISpot assays using splenocytes of vaccinated animals in coculture with DC2.4-SARS2-S cells revealed more than 1,400 IFN-γ secreting cells per $1 \times 10^6$ splenocytes after immunization with MeVvac2-SARS2-S(H) (Fig. 3). In contrast, coculture with splenocytes of control mice resulted in a background response of less than 50 IFN-γ producing cells per $1 \times 10^6$ splenocytes. As expected, restimulation of T cells by DC2.4 presenting no exogenous antigen revealed only reactivity in the range of background (Fig. 3). To rule out clonal or cell line-associated artifacts, antigen-specific IFN-γ secretion by splenocytes of MeVvac2-SARS2-S(H)–vaccinated mice was confirmed by stimulation with transgenic JAWSII-SARS2-S bulk cells. These cells also stimulated in excess of 1,400 IFN-γ secreting cells per $1 \times 10^6$ splenocytes in animals receiving the recombinant SARS-CoV-2 vaccines, whereas only slight background stimulation was observed by the respective controls. The differences between MeV control and MeVvac2-SARS2-S(H) vaccinated mice were statistically significant for both cell lines. Mice vaccinated with Alum-adjuvanted S protein showed no specific reactivity in IFN-γ ELISpot.

Cellular immune responses upon stimulation with MeV bulk antigens were detected in animals that had been vaccinated with any recombinant MeV virus, as expected. While MeV bulk antigens stimulated about 300 to 1,400 IFN-γ secreting cells per $1 \times 10^6$ splenocytes of MeVvac2-ATU(P)–vaccinated animals, spleenocytes of MeVvac2-SARS2-S(H)–vaccinated animals were in a similar range of 400 to 1,400 IFN-γ secreting cells per $1 \times 10^6$ splenocytes. Splenocytes of all animals revealed a similar basic reactivity to unspecific T cell stimulation, as confirmed by numbers of IFN-γ secreting cells upon concanavalin A (ConA) treatment at the limit of detection. Remarkably, stimulation of splenocytes by DC2.4 expressing SARS-CoV-2-S resulted in at
least similar or even higher numbers of IFN-γ+ cells than after stimulation by MeV bulk antigens, indicating an extremely robust induction of cellular immunity against this antigen. Taken together, these data show that MeV vac2-SARS2-S(H) induces not only humoral but also strong SARS-CoV-2 S protein-specific cellular immune responses.

**SARS-CoV-2 S-Reactive T Cells Are Multifunctional.** To gain more detailed insights into the quality of the observed T cell responses, we further characterized the responsive T cell populations by flow cytometry, determining the expression of IFN-γ, TNF-α, and IL-2 in CD8+ and CD4+ positive CD3+ T cells upon restimulation with SARS-CoV-2 S-presenting DC2.4-SARS2-S cells by intracellular cytokine staining (ICS). As a positive stimulus for T cell activation, ionomycin and phorbol myristate acetate (Ionomycin/PMA) were used. Exocytosis of cytokines was blocked by addition of brefeldin A (10 μg/mL) during stimulation. Cells were permeabilized, labeled, and fixed for flow cytometry. The gating strategy excluded duplicates (**SI Appendix, Fig. S6, Middle**, first row), selected for living cells (**SI Appendix, Fig. S6, Right**, first row), and separated CD8+ and CD4+ T cells on CD3+ cell populations (**SI Appendix, Fig. S6, second row**). Selected T cells were then analyzed for their expression of IFN-γ, TNF-α, or IL-2, double-positive (**SI Appendix, Fig. S6, third row**), or triple-positive (**SI Appendix, Fig. S4, fourth row**) cells as exemplarily shown for CD4+ T cells after restimulation with PMA and ionomycin (**SI Appendix, Fig. S7**).

Vaccination with MeV vac2-SARS2-S(H) induced a significant amount of SARS-CoV-2 S-specific CD8+ T cells expressing either IFN-γ (Fig. 4 B, Left), IL-2 (Fig. 4 B, Middle), or TNF-α (Fig. 4 B, Right), with means between 0.02% and 0.5% of positive cells for each of these cytokines. Among those, a significant fraction of cells proved to be multifunctional, with a mean of 47% of the reactive CD8+ cells expressing two cytokines or 13% of responsive CD8+ cells being positive for TNF-α, IL-2, and IFN-γ (**SI Appendix, Fig. S7**). A much lower portion of responsive CD4+ T cells was observed, varying between 0.01% and 0.07% of CD4+ T cells. Among the responsive CD4+ cells, 40% expressed two cytokines and 11% were positive for TNF-α, IL-2, and IFN-γ. Moreover, vaccination induced a significant fraction of vector-specific CD4+ T cells expressing IFN-γ (Fig. 4 A, Left), IL-2 (Fig. 4 A, Middle), or TNF-α (Fig. 4 A, Right) upon restimulation with MeV bulk antigen. Among those, multifunctional CD4+ T cells expressing two or all three cytokines were induced with a mean of about 23% and 6% polyreactive T cells (**SI Appendix, Fig. S7**), respectively. To conclude, vaccination with MeV vac2-SARS2-S(H) induces not only IFN-γ, TNF-α, or IL-2 expressing T cells directed against SARS-CoV-2 and MeV but also a significant fraction of multifunctional cytotoxic T cells specific for SARS-CoV-2 S and CD4+ T cells specific for MeV antigens, illustrating
that a broad and robust SARS-CoV-2–specific immune response is induced by vaccination with MeVvac2-SARS2-S(H).

The reactivity of these T cells also became apparent in a proliferative response to antigen-specific stimulation. Using carboxyfluorescein succinimidyl ester (CFSE)-labeled splenocytes and flow cytometry, we detected significant proliferation of both CD4+ and CD8+ T cells upon stimulation with S-presenting DC2.4 cells only for mice vaccinated with MeVvac2-SARS2-S(H)–vaccinated animals (SI Appendix, Fig. S8).

**Induced T Cells Reveal Antigen-Specific Cytotoxicity.** To demonstrate the effector ability of induced cytotoxic T lymphocytes (CTLs), a killing assay was performed to directly analyze antigen-specific cytotoxicity (Fig. 5). Splenocytes of immunized mice isolated 21 d post boost vaccination were cocultured with DC2.4-SARS2-S or parental DC2.4 cells for 6 d to restimulate antigen-specific T cells. When these restimulated T cells were coincubated with a defined mixture of EL-4green-SARS2-S target and EL-4red control cells (ratio ~1:1), only T cells from MeVvac2-SARS2-S(H)–vaccinated mice significantly shifted the ratio of live SARS-CoV-2 S protein-expressing target cells to control cells in a dose-dependent manner (Fig. 5B). This antigen-dependent killing was also dependent on restimulation with DC2.4-SARS2-S cells, since unstimulated T cells did not significantly shift the ratios of target to nontarget cells (Fig. 5A).

These results indicate that CTLs isolated from MeVvac2-SARS2-S(H)–vaccinated mice are capable of lysing cells expressing SARS-CoV-2 S. Neither splenocytes of control mice restimulated with DC2.4-SARS2-S nor splenocytes of SARS-CoV-2 S protein vaccinated mice restimulated with control DC2.4 cells showed such an antigen-specific killing activity, demonstrating that MeVvac2-SARS2-S(H) induces fully functional antigen-specific CD8+ CTLs.

**Induced Immunity Is Skewed toward Th1-Biased Responses.** While the functionality of both humoral and cellular anti-SARS-CoV-2 immune responses elicited by MeVvac2-SARS2-S(H) is reassuring, the SARS-CoV-2 vaccine development has to proceed with some caution because of the potential risk of immunopathogenesis observed in some animal models, such as antibody-dependent enhancement (ADE) and enhanced respiratory disease (ERD) which seem to correlate with a Th2-biased immune response. Since, in mice, IgG1 is a marker for Th2 bias and risk of ADE development, whereas IgG2a antibodies indicate a favorable Th1 bias, IgG subtype-specific ELISA was performed with the sera collected at different time points. Animals vaccinated with Alum-adjuvanted SARS-CoV-2 S protein, a vaccine concept known for its Th2 bias (11, 12), developed high levels of
S protein-specific IgG1 antibodies, whereas few S-specific IgG2a antibodies were detected (Fig. 6A). In comparison, MeV vac-SARS2-S(H) induced 100-fold fewer IgG1 antibodies, but at least 10-fold higher IgG2a levels (Fig. 6A), indicating a favorable Th1 bias in animals immunized with the MeV-derived vaccine candidate.

These findings were confirmed by multiplex cytokine analysis of the cytokine profile in the supernatants of splenocytes from vaccinated animals, which were restimulated using DC2.4 or DC2.4-SARS2-S cells. All splenocytes of representative animals revealed secretion of all cytokines after stimulation with ConA, demonstrating general reactivity of cells and assay (SI Appendix, Fig. S9). Most likely due to the low number of S-reactive T cells in animals that had been vaccinated with recombinant SARS-CoV-2 S protein and Alum, no, or minimal, constant cytokine levels were measurable in the supernatants of restimulated splenocytes (Fig. 6B). In contrast, splenocytes of animals immunized with MeV vac-SARS2-S(H) reacted specifically with the secretion of IFN-γ, TNF-α, and IL-2 upon restimulation by DC2.4-SARS2-S (Fig. 6B), in accordance with ELISpot (Fig. 3) and ICS data (Fig. 4). However, we could observe no or minimal up-regulation of IL-4, IL-5, IL-13, or IL-10, which would have been indicative for a Th2-biased response (Fig. 6B). Also, IL-17a or IL-6 indicative of a Th17 or general inflammatory response, respectively, showed minimal changes (Fig. 6B).

Thus, both humoral and cellular responses reveal a Th1-biased immunity induced by MeV vac-SARS2-S(H), which indicates a relatively low risk for putatively Th2-mediated immunopathologies.

Fig. 5. Antigen-specific killing activity of SARS-CoV-2 S-specific T cells. Killing assay using splenocytes of mice vaccinated on days 0 and 28 isolated 21 d after the second immunization. Splenocytes were cocultured (A) with DC2.4 or (B) with antigen-presenting DC2.4-SARS2-S cells for 6 d. Activated CTLs were then cocultured with EL4 green-SARS2-S target cells (Antigen) and EL4 red control cells (NC) at indicated E:T ratios for 4 h. Ratio of living target to nontarget cells (Antigen:NC) was determined by flow cytometry. Depicted are means and SD of each group (open diamonds, MeV vac-SARS2-S(H); filled circles, mock; filled squares, MeV vac-ATU(P); gray triangles, S protein + Alum) (n = 4 to 6). For statistical analysis, two-way ANOVA analysis was applied with paired Tukey’s multicomparison test used as post hoc test. E:T, effector cell : target cell ratio; ****P < 0.0001.

MeV-COVID-19 Vaccine-Induced Immune Responses Are Effective In Vivo. To finally test antiviral efficacy and the protective capacity of the immune responses induced by our COVID-19 vaccine candidate, two different animal models of COVID-19 were used. On the one hand, we established the Syrian golden hamster model for SARS-CoV-2–induced disease, which revealed remarkably severe outcomes. Using an available low-pathogenic SARS-CoV-2 patient isolate for intranasal challenge of 6- to 12-wk-old hamsters, the infected animals developed severe pneumonia with an impressive gross pathology (SI Appendix, Fig. S10 A and B) that necessitated killing four out of six animals within 5 d to 6 d postinfection (SI Appendix, Fig. S10C). To take advantage of this model, hamsters were vaccinated with MeV vac-SARS2-S(H), MeV vac-ATU(H) as vector control, Alum-adjuvanted SARS-CoV-2 Spike protein as vaccine control, or medium (mock) in a prime–boost scheme for challenge. These hamsters showed induction of anti-MeV and anti-SARS-CoV-2 humoral immune responses with neutralizing antibody titers against SARS-CoV-2 between 15 and 80 VNT corresponding to 20 to 213 PRNT50 (50% plaque reduction neutralization titer), exceeding those of the Alum-S vaccine control group (SI Appendix, Fig. S11 F and M). Upon challenge, the initial weight loss observed in all groups was stopped in the MeV vac-SARS2-S(H) cohort on day 3 postinfection, and animals started to gain weight, whereas all other groups revealed progressive weight loss (Fig. 7A). The experimental animals stopped 4 d postinfection to determine live virus titers (Fig. 7B) as well as virus genome copy numbers (Fig. 7C) in relevant tissues, that is, lungs and nasal turbinates. The corresponding data reflected the observations on gross pathology (Fig. 7A and SI Appendix, Fig. S12): The hamsters vaccinated with MeV vac-SARS2-S(H) had a more than 10-fold reduction in virus genomes in lungs and nasal turbinates than all other groups (Fig. 7C), corresponding to absence of live virus in the lungs of five out of six and nasal turbinates of one out of six vaccinated animals (Fig. 7B). Thus, vaccination with MeV vac-SARS2-S(H) significantly ameliorated virus loads in infected animals and protected them against severe pathology in this remarkably aggressive challenge model. In this model, SARS-CoV-2 neutralization antibody titers in MeV vac-SARS2-S(H)–vaccinated hamsters showed a tendency to reverse correlate with weight loss and RNA copy numbers in lungs and nasal turbinates, indicating some role of neutralizing antibodies in fighting disease progression (Fig. 7D).

Our second animal model confirmed these observations. Virus loads of the mouse-adapted SARS-CoV-2 MA (13) were significantly reduced in the lungs of vaccinated mice (corresponding immunity data in SI Appendix, Fig. S13), and revealed a tendency for reduced titers in nasal turbinates, as well (Fig. 7E), in the absence of gross pathology in both groups. Therefore, both challenge models show protective efficacy of the immune responses induced by MeV vac-SARS2-S(H).

Discussion
In this study, we aimed to analyze the efficacy of MeV-derived vaccine candidates encoding the Spike glycoprotein S of SARS-CoV-2 to induce functional immune responses to protect against COVID-19. We show that MeV vac-SARS2-S(H) replicated comparably to MeV vaccine strain viruses and was genetically stable over extended passaging. Upon vaccination of mice, it induced robust humoral immune responses of the IgG2a subtype directed against the SARS-CoV-2 spike glycoprotein S with neutralizing activity in a range already shown to be protective by others. In addition, considerable amounts of SARS-CoV-2 S-specific CD4+ and CD8+ T cells were induced, the major fraction of which were secreting two or even all three cytokines when analyzing for IFN-γ, TNF-α, or IL-2 upon antigen-specific restimulation. These T cells proliferated and specifically depleted antigen-positive target cells in a mixed population. Importantly, all responses were skewed toward Th1-biased immunity.

In parallel,
the capacity to induce measles-specific immune reactivity remained conserved. Finally, the induced immunity conferred protection in two different animal models of SARS-CoV-2 infection, Syrian golden hamsters inoculated with a low-passage patient isolate and mice challenged with a mouse-adapted recombinant SARS-CoV-2 MA. This effective MeV Moraten strain-derived recombinant vaccine MeVvac2-SARS2-S(H) is a live-attenuated vaccine that encodes the full-length, functional version of the SARS-CoV-2 S protein as the main target for functional antibodies, but also for induction of T cell responses. Vero cells revealed homogenous expression of the SARS-CoV-2 S antigen by Western blot analyses and positive immunostaining of syncytia after infection by MeVvac2-SARS2-S(H). Stable antigen expression is a prerequisite for the immune system to encounter the specific antigen to mount robust immune responses and for industrial production of a vaccine. Indeed, IFNAR−/−CD46Ge mice vaccinated with MeVvac2-SARS2-S(H) in a prime–boost protocol showed uniform induction of antibodies directed against MeV bulk antigens or SARS-CoV-2 S, which had considerable neutralizing activity against both pathogens. We observe antibody responses in these animals at a level that correlates with protection in mouse challenge models (14), as well as with neutralizing activity we found in the serum of four reconvalescent human patients. These responses were triggered despite the knockout of the type I IFN receptor, which is necessary to allow propagation of MeV in mice (10, 15). This knockout usually should impair the induction of especially humoral immune responses (16). This highlights the remarkable immunogenicity of the MeV vaccine platform technology that also works in this model with partially impaired immune responses.

However, why did not all immunized animals develop neutralizing activity detectable in our assay? Firstly, determination of the VNT relying on 100% pathogen neutralization is obviously a rather harsh assay in the context of SARS-CoV-2, as evidenced by the modest VNT titers published so far, in general, and absence of VNT in the S+Alum vaccinated group despite high amounts of S-binding antibodies. This means that just detectable VNT already indicates considerable neutralizing activity. Indeed, when testing the sera of mice that were later on challenged with SARS-CoV-2 MA in parallel for VNT and PRNT50 titers, two animals negative for VNT became positive in PRNT50. Secondly, we realized that three of the four animals which did not show a VNT of >10 did not respond well to the prime vaccination, at all. These animals developed no or only a minor VNT against MeV after the first vaccination. This observation is rather unusual, and argues for technical issues during the first vaccination in these

Fig. 6. Immune bias of induced responses. To analyze skewing of immune responses toward Th1- or Th2-biased immunity, (A) sera and (B) splenocytes of vaccinated mice depicted before were analyzed. (A) Sera of mice vaccinated on days 0 and 28 with MeVvac2-SARS2-S(H) or Alum-adjuvanted S protein already shown in Fig. 2 were analyzed for IgG1- or IgG2a-type antibodies specific for SARS-CoV-2 S. IgG1 (Left) or IgG2a (Right) binding to recombinant SARS-CoV S were determined by ELISA via the specific optical density (OD) 450-nm value. Depicted are means and respective SD of the mean (SEM) of each group (n = 6 to 7). (B) Splenocytes of the same mice already shown in Figs. 3–S and SI Appendix, Fig. S8 were analyzed by multiplex cytokine analysis for secretion of typical marker cytokines in the supernatant after restimulation by coculture with antigen-presenting DC2.4-SARS2-S cells. DC2.4 cells served as nonspecific control stimulus. Dots represent individual animals; horizontal bars are mean per group (n = 4 to 5). IFN-γ: upper limit of detection (ULOD): 2,015.2 pg/mL; IL-6: ULOD: 3,992.4 pg/mL; IL-17a lower limit of detection (LLOD): 0.473 pg/mL; IL-4 LLOD: 0.095 pg/mL; IL-5 LLOD: 0.685 pg/mL; IL-13 LLOD: 3.463 pg/mL. For statistical analysis of grouped multiplex data, two-way ANOVA analysis was applied with paired Tukey’s multicomparsion test as post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001.
Virus titration in lungs or nasal turbinates (intranasally challenged with SARS-CoV-2 or mouse-adapted SARS-CoV-2 MA, respectively, and protection was analyzed by quantifying weight loss). These so-called oncolytic MeV have been used in 15 phase I and II clinical trials for treatment of tumor patients, which revealed an extremely beneficial safety profile of this recombinant vaccine concept also in human patients, while signs of efficacy became evident.

In any case, generation of MeV-derived COVID-19 vaccines encoding a less fusion-active variant of the SARS-CoV-2 S glycoprotein might be beneficial to enhance titers of the vaccine virus. In the meantime, stabilized S variants have become available that have attenuated or no cell-fusion activity. One variant has a deletion of the multibasic cleavage motif for furin-like proteases at the S1/S2 boundary that facilitates preactivation of S (25). A second variant has proline substitutions at residues 986 and 987, which are stabilizing a prefusion conformation of S (26). Vaccine candidates encoding S with one of these motifs or a combination thereof in a soluble version, as already done for DNA vaccines (27), are under development. These have to show not just a matter of cell entry tropism and mechanism (22). Likewise, the clinical phase 1 and 2 trials using the MeV vector platform for the generation of bivalent vaccines, which induce immunity against Chikungunya virus (CHIKV) (23, 24), have revealed an extremely beneficial safety profile of this recombinant vaccine candidate also in human patients, while signs of efficacy became evident.

In any case, generation of MeV-derived COVID-19 vaccines encoding a less fusion-active variant of the SARS-CoV-2 S glycoprotein might be beneficial to enhance titers of the vaccine virus. In the meantime, stabilized S variants have become available that have attenuated or no cell-fusion activity. One variant has a deletion of the multibasic cleavage motif for furin-like proteases at the S1/S2 boundary that facilitates preactivation of S (25). A second variant has proline substitutions at residues 986 and 987, which are stabilizing a prefusion conformation of S (26). Vaccine candidates encoding S with one of these motifs or a combination thereof in a soluble version, as already done for DNA vaccines (27), are under development. These have to show not just a matter of cell entry tropism and mechanism (22).

Also, extended passaging of the vaccine candidate did not result in changes of the vaccine, as revealed by sequencing of the virus after 10 passages starting with a low multiplicity of infection (MOI). This genetic stability indicates that the slight impairment seen in multistep growth curves when compared to a vaccine-strain MeV is not critical for the vaccine’s amplification and therefore crucial for product safety. In accordance with its genetic stability, the minor enhancement of fusion activity can also be regarded as noncritical, especially when considering the fusion activity of MeV used in clinical trials for treatment of tumors. These so-called oncolytic MeV have been used in 15 phase 1 and phase 2 clinical trials, so far. Thereby, advanced-stage tumor patients suffering from different tumor entities have been treated. Despite constituting, in principle, a vulnerable patient collective, application of high doses of nontargeted, fusion-active MeV (up to $1 \times 10^{11}$ TCID$_{50}$) (19) systemically or, for example, directly into the patients’ brains (20) was accompanied by an acceptable safety profile (21). Therefore, the enhancement of fusion activity cannot be expected to be crucial for product safety, while the attenuation of vaccine-strain MeV is multifactorial, anyway, and not just a matter of cell entry tropism and mechanism (22).
The induction of the "right" antibodies and T cell responses is especially crucial when taking potential complications into consideration that can be observed when coronavirus encounters "wrong" immune responses that can give rise to immunopathologies after infection. In some infected cats, infection with feline coronavirus causes feline infectious peritonitis, a deadly disease characterized by viral infection of macrophages during the acute phase. Interestingly, the switch of pathology after infection from a rather moderate pathogenesis into an acute, devastating disease can be triggered by vaccination of persistently infected cats and has been attributed to the induction of antibodies that mediate enhancement of the disease, a process called ADE. During COVID-19, ADE might be the cause of the severe cases currently observed. Some case reports indicate that severe disease appeared more frequently in patients with high SARS-CoV-2 IgG levels (28). ADE has been most prominent for dengue virus (DENV) infections, especially in secondary infections with a different DENV serotype where enhancement of disease correlated with the induction of nonneutralizing Abs that can mediate an efficient uptake of the virus into FcR-positive cells such as macrophages and other immune cells (29). Moreover, other immune-related adverse events were described for SARS- and MERS-CoV. When animals were immunized with vaccines that predominantly induce Th2-biased T-helper cell responses, vaccination revealed significantly reduced virus loads after challenge, but also an eosinophilic infiltrate into the lungs accompanied by pathological changes of the lung tissue, so-called ERD (30). Such immunopathologies upon CoV infection are a major concern for diseases pathology and, especially, vaccine development. Thus, Th2-biased immune responses as triggered by alum-adjuvanted whole inactivated virus particles or recombinant proteins should be avoided.

Interestingly, the live-attenuated MeV vaccine is known for a balanced Th1/Th2 bias of induced immune responses, with a bias for Th1 responses at least during the acute phase after vaccination (31). In theory, this should also apply for immune responses induced against all antigens presented during an MeV vaccine virus infection including foreign antigen(s) additionally expressed when MeV is used as vaccine platform. Indeed, our analyses provide evidence that the bias of the immune responses is in favor of Th1 responses, as revealed by the inverted IgG1/IgG2a ratio of the antibodies induced against SARS-CoV-2 S by MeVvac2-SARS2-S(H) compared to the animals immunized with alum-adjuvanted recombinant S protein. Moreover, the cytokine profile of splenocyte cultures of immunized mice after restimulation of S-specific T cells reveals a preferable Th1 bias. Since SARS-CoV-2 and SARS-CoV use the same primary attachment receptor for cell entry, hACE2, and selected hACE2-transgenic mice show different pathology after inoculation with SARS-CoV-2 (14, 32), studying the impact of the Th1-biased MeV-based immunization in hACE2-transgenic mice during challenge with SARS-CoV-2 will be a matter for future studies. In any case, our challenge data also reveal that MeV-derived COVID-19 vaccines have a low likelihood to trigger immunopathogenesis, but we show considerable antiviral efficacy, especially in the Syrian hamster model. This animal model is susceptible for SARS-CoV-2 infection and suitable for vaccination using recombinant MeV (33); reveals in our setting a moderate to severe, clearly distinguishable pathology, and shows airborne transmissibility from infected to naive animals. Therefore, this animal model accurately reflects at least some aspects of the course of human disease and reveals the potential of our candidate to vaccinate effectively against COVID-19.

In conclusion, the bivalent MeV/SARS-CoV-2 vaccine candidate has a number of desirable properties with respect to its immunogenicity and efficacy against SARS-CoV-2. Furthermore, the concurrent induction of anti-MeV immunity would allow its use in the context of routine measles immunization schedules. Such an MeV-based COVID-19 vaccine could be included in the currently applied MMR (measles, mumps, rubella) vaccine, providing additional protection against SARS-CoV-2. While there is controversy regarding to what extent it occurs, children do become infected and shed the virus, despite them rarely being severely affected. In any case, preventing or reducing infection or virus shedding from vaccinated children can also help to contain the disease and protect vulnerable groups (34). Furthermore, the vaccinated children themselves could be protected against newly described side effects of COVID-19 infections, such as Multisystem Inflammatory Syndrome, affecting also the cohort of (very) young patients (34). Therefore, the capacity to produce large amounts of vaccine doses as well as the respective distribution network would be available more or less instantly from routine measles vaccine production, but at no impairment of production of other necessary vaccines, since the measles vaccine property is preserved in the proposed vaccine candidate. Especially since vaccination against the measles should not be impaired also during the COVID-19 epidemic, this is a considerable advantage. Otherwise, parallel epidemics with another, even more contagious respiratory virus are looming when vaccination programs against the measles are stopped in favor of COVID-19 vaccination programs. However, while we envision primarily pediatric application for this vaccine candidate, currently available data also suggest applicability of MeV-derived recombinant bivalent vaccines also in vaccinees with preformed anti-measles immunity. The performance of measles-derived recombinant vaccine targeting HIV-1 or CHIKV has been analyzed in vivo in respective models in measles-vaccinated animals. In both mice and nonhuman primates, at least antibodies against the secondary target pathogen were successfully induced also in preimmune animals (35, 36). This was reflected by the outcome of phase I and phase II clinical studies of an MeV-CHIKV vaccine candidate. Also, in human vaccinees, induction of significant anti-CHIKV antibody titers independent from the preimmunity seen in the respective individuals has been observed (23, 24). Future studies have to demonstrate that this is also the case for MeV-derived COVID-19 vaccine candidates. Taken together, MeVvac2-SARS2-S(H) is a promising vaccine candidate that warrants further investigation.

Materials and Methods

Detailed descriptions of the materials, methods, and equipment used in this work, including cells, plasmids, production of lentiviral vectors and generation of antigen-expressing dendritic cell lines, viruses, MeV genome sequence analysis, NGS library preparation and sequencing, RNA sequence analysis, immunoperoxidase monolayer assay, Western blot analysis, animal experiments, total IgG and IgG1/IgG2a quantification, Th1/Th2 cytokine multiplex array, virus neutralization test, plaque reduction neutralization test, IPV-ELISpot analysis, ICS, T cell proliferation assay, CTL killing assay, virus titers in organs of infected animals, RNA preparation, quantitative RT-PCR, and statistical analyses, are provided in S1 Appendix, Supplementary Extended Materials and Methods.

Data Availability. All data are provided in the manuscript and S1 Appendix. The sequence data for the vaccine candidate described in this paper have been deposited in the GenBank Data Bank (accession no. MW090917).

ACKNOWLEDGMENTS. This work was supported by the German Center for Infection Research (unit TTU 01.805 and flex-fund TTU 01.922.00) and the German Ministry of Health. We would like to thank Daniela Müller and Carina Krup for excellent technical assistance, Björn Becker for assistance in multiplex analysis, Gabas Miskey for assistance with NGS, Christel Kamp for excellent advice on statistics, and Marcel Rommel for cell sorting. We are indebted to Gerhard Dobler for providing SARS-CoV-2 isolate MUC-M1B1, Maria Vehreschild for human patient responsive viral, Kenneth Rock for DC2.4 cells, Roberto Cattaneo for providing the pBR(e)MVvac2 construct, and Urs Schneider for providing the Polii rescue system used to generate and to rescue recombinant MeV vectors. We would further like to thank Bakhos Tannous for providing pGCSW2gluc-IRIS-GFP. The research reagent for SARS-CoV-2 RNA (NIBSC 19/304) was obtained from the National Institute for Biological Standard and Control, United Kingdom. Moreover, we would like to thank Roberto Cattaneo and Veronika von Mesling for valuable comments on the manuscript.

Hörner et al. PNAS Latest Articles 9 of 10
1. F. Wu et al., A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
2. Q. Li et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020).
3. R. Li et al., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368, 489–493 (2020).
4. M. D. Mühlebach, Vaccine platform recombinant measles virus. Virus Genes 53, 733–740 (2017).
5. N. Escriva et al., Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology 452-453, 32–41 (2014).
6. M. Liniger et al., Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26, 2164–2174 (2008).
7. A. H. Malczyk et al., A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J. Virol. 89, 11654–11667 (2015).
8. B. S. Bodmer et al., A new coronavirus associated with human respiratory disease in China. Nature 579, 123–129 (2020).
9. S. Heidmeier et al., A single amino acid substitution in the measles virus F2 protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains. Virus Res. 180, 43–48 (2014).
10. B. Mrkic et al., Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 72, 7420–7427 (1998).
11. P. Marrack, A. S. McKee, M. W. Munks, Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287–293 (2009).
12. P. He, Y. Zou, Z. Hu, Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccin. Immunother. 11, 477–488 (2015).
13. K. H. Dinnon 3rd et al., A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566 (2020).
14. R.-D. Jiang et al., Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50–58.e8 (2020).
15. M. Mura et al., hCD46 receptor is not required for measles vaccine Schwarz strain replication in vivo: Type-I IFN is the species barrier in mice. Virology 524, 151–159 (2018).
16. A. Le Bon et al., Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461–470 (2001).
17. I. J. Amanna, N. E. Carlson, M. K. Silfva, Duration of humoral immunity to common viral and vaccine antigens. N Engl. J. Med. 357, 1903–1915 (2007).
18. S. Carrny, M. Feysaqualet, M. Povey, E. Di Paola, Long-term immunogenicity of measles, mumps and rubella containing vaccines in healthy young children: A 10-year follow-up. Vaccine 37, 5323–5331 (2019).
19. S. J. Russell et al., Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 89, 926–933 (2014).
20. P. Muaouel et al., Clinical trials with oncolytic measles virus: Current status and future prospects. Curr. Cancer Drug Targets 18, 177–187 (2018).
21. A. Dispenziere et al., Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791–2798 (2017).
22. D. E. Griffin, W.-H. W. Lin, A. N. Nelson, Understanding the causes and consequences of measles virus persistence. F1000Res. 7, 237 (2018).
23. K. Rasmussen et al., Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15, 519–527 (2015).
24. E. C. Reisinger et al., Immunogenicity, safety, and tolerability of the measles-vectored Chikungunya Virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 392, 2718–2727 (2019).
25. M. Hoffmann et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
26. D. Wrap et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
27. J. Yu et al., DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811 (2020).
28. N. M. A. Okba et al., Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478–1488 (2020).
29. F. A. Rey, K. Stiasny, M.-C. Vaney, M. Dellarole, F. X. Heinz, The bright and the dark side of human antibody responses to flaviviruses: Lessons for vaccine design. EMBO Rep. 19, 206–224 (2018).
30. L. Liu et al., Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).
31. D. Naniche, Human immunology of measles virus infection. Curr. Top. Microbiol. Immunol. 330, 151–171 (2009).
32. L. Bao et al., The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833 (2020).
33. M. Yoneda et al., Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One 8, e58414 (2013).
34. E. M. Dufort et al., New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team, Multisystem inflammatory syndrome in children in New York State. N. Engl. J. Med. 383, 347–358 (2020).
35. C. Lorin et al., A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78, 146–157 (2004).
36. S. Brandler et al., A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31, 3718–3725 (2013).